AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 111 filers reported holding AKERO THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 8.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,306,751 | +2.0% | 45,606 | -5.9% | 0.00% | 0.0% |
Q2 2023 | $2,262,177 | +61.5% | 48,451 | +32.3% | 0.00% | – |
Q1 2023 | $1,400,966 | +1307.0% | 36,617 | +1915.2% | 0.00% | – |
Q4 2022 | $99,571 | -93.4% | 1,817 | -95.9% | 0.00% | – |
Q3 2022 | $1,506,000 | +8758.8% | 44,235 | +2354.8% | 0.00% | – |
Q2 2022 | $17,000 | -70.7% | 1,802 | -55.9% | 0.00% | – |
Q1 2022 | $58,000 | -78.8% | 4,088 | -68.4% | 0.00% | – |
Q4 2021 | $274,000 | +2390.9% | 12,950 | +2614.9% | 0.00% | – |
Q3 2021 | $11,000 | +83.3% | 477 | +110.1% | 0.00% | – |
Q2 2021 | $6,000 | -45.5% | 227 | -39.8% | 0.00% | – |
Q1 2021 | $11,000 | -98.6% | 377 | -98.7% | 0.00% | – |
Q4 2020 | $774,000 | +294.9% | 30,022 | +369.6% | 0.00% | – |
Q3 2020 | $196,000 | -63.2% | 6,393 | -70.0% | 0.00% | – |
Q2 2020 | $532,000 | +309.2% | 21,334 | +247.2% | 0.00% | – |
Q1 2020 | $130,000 | +85.7% | 6,145 | +94.2% | 0.00% | – |
Q4 2019 | $70,000 | +677.8% | 3,164 | +719.7% | 0.00% | – |
Q3 2019 | $9,000 | – | 386 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Skorpios Trust | 3,271,829 | $125,180,178 | 50.58% |
COMMODORE CAPITAL LP | 790,000 | $30,225,400 | 4.60% |
Redmile Group, LLC | 2,044,389 | $78,218,323 | 3.39% |
SILVERARC CAPITAL MANAGEMENT, LLC | 202,561 | $7,749,984 | 3.20% |
Ghost Tree Capital, LLC | 275,000 | $10,522,000 | 3.11% |
Avidity Partners Management LP | 2,447,000 | $93,622,220 | 3.11% |
Atlas Venture Life Science Advisors, LLC | 594,251 | $22,736,043 | 3.08% |
Logos Global Management LP | 400,000 | $15,304,000 | 2.19% |
Yiheng Capital Management, L.P. | 1,125,791 | $43,072,764 | 1.70% |
Boxer Capital, LLC | 831,495 | $31,813 | 1.56% |